Plain-English translation of NCT03529110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested a new medication called trastuzumab deruxtecan (also known as DS-8201a) to see if it worked better than an existing breast cancer treatment called T-DM1. Both medications are antibody drug conjugates—special drugs designed to target and attack cancer cells that have a protein called HER2 on their surface. The trial studied people whose advanced breast cancer had already been treated with other HER2-targeted drugs and chemotherapy.
Many people with advanced HER2-positive breast cancer eventually stop responding to standard treatments. This medication was being tested to see if it could help people whose cancer had progressed despite earlier treatment, and whether it might work better or be safer than the existing option.
Participants were randomly assigned to receive either the new medication or the standard treatment, both given as intravenous infusions every 3 weeks. The trial involved regular visits to the hospital or clinic for treatment and follow-up scans and blood tests to monitor how well the medication was working and check for any side effects. The exact length of participation depended on how the individual responded to treatment.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States